While the share of ESI enrollees with a GLP-1 drug claim has been increasing, still only a relatively modest number of people have a claim Since 2012, the share of non-elderly adults with ESI that have a GLP-1 drug claim has grown more than eightfold (717.7% increase)
They then collected follow up data for up to 18 months to see who was later diagnosed with ischemic optic neuropathy
Monitor your blood sugar and treat low blood sugar levels as your doctor has instructed
Similar content being viewed by others Subjects Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have emerged as a transformative class of therapeutics that promote weight loss, improve glycemic control, and provide systemic benefits across multiple organ systems 1,2,3,4
Efficacy of semaglutide vs
While the high upfront cost of these drugs is a significant barrier, they could represent a significant source of savings in the later years from lower rates of obesity, cardiovascular, and kidney disease